Overview

Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2010-11-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Belimumab